Hinova Pharmaceuticals Inc. A - Asset Resilience Ratio

Latest as of June 2025: 15.84%

Hinova Pharmaceuticals Inc. A (688302) has an Asset Resilience Ratio of 15.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688302 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥220.52 Million

≈ $32.27 Million USD Cash + Short-term Investments

Total Assets

CN¥1.39 Billion

≈ $203.78 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Hinova Pharmaceuticals Inc. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hinova Pharmaceuticals Inc. A assets under control.

Liquid Assets Composition Over Time

This chart breaks down Hinova Pharmaceuticals Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688302 liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥220.52 Million	15.84%
Total Liquid Assets	CN¥220.52 Million	15.84%

Asset Resilience Insights

Good Liquidity Position: Hinova Pharmaceuticals Inc. A maintains a healthy 15.84% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Hinova Pharmaceuticals Inc. A Industry Peers by Asset Resilience Ratio

Compare Hinova Pharmaceuticals Inc. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Hinova Pharmaceuticals Inc. A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Hinova Pharmaceuticals Inc. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.46%	CN¥210.49 Million ≈ $30.80 Million	CN¥1.36 Billion ≈ $199.24 Million	-4.03pp
2023-12-31	19.48%	CN¥290.62 Million ≈ $42.53 Million	CN¥1.49 Billion ≈ $218.26 Million	-1.62pp
2022-12-31	21.11%	CN¥366.24 Million ≈ $53.59 Million	CN¥1.74 Billion ≈ $253.90 Million	+13.28pp
2019-12-31	7.83%	CN¥3.50 Million ≈ $512.16K	CN¥44.72 Million ≈ $6.54 Million	--

pp = percentage points

About Hinova Pharmaceuticals Inc. A

SHG:688302 China Biotechnology

Market Cap

$486.83 Million

CN¥3.33 Billion CNY

Market Cap Rank

#12571 Global

#3720 in China

Share Price

CN¥33.60

Change (1 day)

+2.03%

52-Week Range

CN¥29.13 - CN¥57.00

All Time High

CN¥74.97